Editas Medicine, Inc. (0IFK.L)
USD 1.46
(-4.63%)
USD 1.46
(-4.63%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -163.11 Million USD | 27.81% |
| 2022 | -219.61 Million USD | -16.98% |
| 2021 | -188.09 Million USD | -43.24% |
| 2020 | -130.88 Million USD | 4.41% |
| 2019 | -138.09 Million USD | -24.39% |
| 2018 | -110.47 Million USD | 4.98% |
| 2017 | -116.66 Million USD | -22.73% |
| 2016 | -96.06 Million USD | -33.66% |
| 2015 | -72.28 Million USD | -439.18% |
| 2014 | -13.49 Million USD | -158.65% |
| 2013 | -5.21 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -65.58 Million USD | -191.53% |
| 2024 Q2 | -70.48 Million USD | -7.47% |
| 2024 Q3 | -62.14 Million USD | 14.1% |
| 2023 Q4 | -22.49 Million USD | 50.03% |
| 2023 FY | - USD | 27.81% |
| 2023 Q1 | -50.96 Million USD | 19.68% |
| 2023 Q2 | -44.09 Million USD | 13.48% |
| 2023 Q3 | -45.01 Million USD | -2.1% |
| 2022 Q2 | -52.63 Million USD | -7.0% |
| 2022 FY | - USD | -16.98% |
| 2022 Q1 | -49.19 Million USD | -18.22% |
| 2022 Q4 | -63.44 Million USD | -13.47% |
| 2022 Q3 | -55.91 Million USD | -6.23% |
| 2021 Q4 | -41.6 Million USD | -9.32% |
| 2021 Q1 | -56.88 Million USD | 13.65% |
| 2021 Q2 | -55.4 Million USD | 2.61% |
| 2021 Q3 | -38.06 Million USD | 31.3% |
| 2021 FY | - USD | -43.24% |
| 2020 Q1 | -39.28 Million USD | 0.33% |
| 2020 FY | - USD | 4.41% |
| 2020 Q4 | -65.87 Million USD | -832.83% |
| 2020 Q3 | 8.98 Million USD | 129.5% |
| 2020 Q2 | -30.46 Million USD | 22.44% |
| 2019 Q3 | -33.86 Million USD | 5.2% |
| 2019 FY | - USD | -24.39% |
| 2019 Q4 | -39.41 Million USD | -16.4% |
| 2019 Q2 | -35.71 Million USD | -14.09% |
| 2019 Q1 | -31.3 Million USD | -19.23% |
| 2018 Q3 | -15.41 Million USD | 60.97% |
| 2018 Q4 | -26.25 Million USD | -70.28% |
| 2018 FY | - USD | 4.98% |
| 2018 Q1 | -30.8 Million USD | 15.16% |
| 2018 Q2 | -39.5 Million USD | -28.22% |
| 2017 FY | - USD | -22.73% |
| 2017 Q1 | -29.99 Million USD | 23.12% |
| 2017 Q2 | -25.46 Million USD | 15.11% |
| 2017 Q3 | -26.55 Million USD | -4.28% |
| 2017 Q4 | -36.31 Million USD | -36.76% |
| 2016 Q4 | -39.01 Million USD | -84.38% |
| 2016 FY | - USD | -33.66% |
| 2016 Q3 | -21.16 Million USD | -11.65% |
| 2016 Q2 | -18.95 Million USD | -7.19% |
| 2016 Q1 | -17.68 Million USD | -40.34% |
| 2015 Q2 | -10.28 Million USD | -98.73% |
| 2015 Q3 | -7.25 Million USD | 29.53% |
| 2015 Q1 | -5.17 Million USD | 2.85% |
| 2015 Q4 | -12.59 Million USD | -73.78% |
| 2015 FY | - USD | -439.18% |
| 2014 FY | - USD | -158.65% |
| 2014 Q3 | -3.08 Million USD | -41.74% |
| 2014 Q4 | -5.32 Million USD | -72.63% |
| 2014 Q2 | -2.17 Million USD | 0.0% |
| 2014 Q1 | -2.17 Million USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Dynavax Technologies Corporation | 9.66 Million USD | 1787.534% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 266.002% |
| Perrigo Company plc | 646.2 Million USD | 125.242% |
| Illumina, Inc. | -608 Million USD | 73.172% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 101.51% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 63.672% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 98.554% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 105.01% |
| Heron Therapeutics, Inc. | -103.79 Million USD | -57.158% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 103.505% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -337.51% |
| Waters Corporation | 1.02 Billion USD | 115.957% |
| Biogen Inc. | 2.37 Billion USD | 106.862% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | -86.575% |
| Evolus, Inc. | -41.81 Million USD | -290.139% |
| Adicet Bio, Inc. | -136.53 Million USD | -19.469% |
| Cara Therapeutics, Inc. | -117.65 Million USD | -38.646% |
| bluebird bio, Inc. | -167.16 Million USD | 2.419% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | -8.666% |
| FibroGen, Inc. | -261.4 Million USD | 37.6% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 109.727% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -267.077% |
| Homology Medicines, Inc. | -47.75 Million USD | -241.563% |
| Geron Corporation | -174.78 Million USD | 6.674% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 28.495% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | -77.149% |
| Myriad Genetics, Inc. | -67.8 Million USD | -140.586% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -61.779% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 67.783% |
| Zoetis Inc. | 3.68 Billion USD | 104.427% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -222.544% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 114.013% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 152.57% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 103.542% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -352.073% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 29.083% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 38.677% |
| Verastem, Inc. | -83.16 Million USD | -96.134% |
| Nektar Therapeutics | -243.1 Million USD | 32.903% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 27.501% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | -85.392% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 62.86% |
| OPKO Health, Inc. | -65.51 Million USD | -148.973% |
| Exelixis, Inc. | 196.6 Million USD | 182.968% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 139.201% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 250.583% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -192.555% |
| uniQure N.V. | -253.1 Million USD | 35.552% |
| Imunon, Inc. | -20.78 Million USD | -684.885% |
| Blueprint Medicines Corporation | -474.61 Million USD | 65.632% |
| Insmed Incorporated | -654.73 Million USD | 75.087% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 136.092% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 52.783% |
| TG Therapeutics, Inc. | 26.1 Million USD | 724.969% |
| Incyte Corporation | 919.42 Million USD | 117.741% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 67.719% |